ATOSSA THERAPEUTICS, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(amounts in thousands, except share and per share data)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development | $3,378 | $5,370 | $13,054 | $15,029 |
| General and administrative | 2,521 | 3,881 | 11,409 | 10,676 |
| Total operating expenses | 5,899 | 9,251 | 24,463 | 25,705 |
| Operating loss | (5,899) | (9,251) | (24,463) | (25,705) |
| Interest income | 209 | 570 | 745 | 1,935 |
| Other income (expense), net | 52 | (11) | — | (63) |
| Loss before income taxes | (5,638) | (8,692) | (23,718) | (23,833) |
| Income tax benefit | — | — | — | — |
| Net loss | (5,638) | (8,692) | (23,718) | (23,833) |
| Net loss per share of common stock - basic and diluted | $(0.56) | $(1.01) | $(2.58) | $(2.76) |
| Weighted average shares outstanding used to compute net loss per share - basic and diluted | 9,990,226 | 8,622,289 | 9,178,686 | 8,622,289 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.